

# Scientific Program

Thursday, February 28, 2013

7:30 Onwards	Registration		
08:50-10:00	Inauguration		Bhargava Auditorium
10:15-10:30	Inauguration of Trade Exhibition		
10:30-11:00	Tea		
11:00-13:00	<b>SCIENTIFIC SESSION I Radionuclide Generators: Past, Present and Future</b>		
	<b>Chairpersons</b>	<b>ML Thakur, Uday Bhonsle, Christof Seidl, Shashi Singh, Pat Donahue</b>	<b>Speakers</b>
11:00-11:25	S 001	<sup>68</sup> Ge/ <sup>68</sup> Ga generators and <sup>68</sup> Ga radiopharmaceutical chemistry on their way into a new century	Frank Roesch (Mainz, Germany)
11:25-11:45	S 005	An increasing role for generator produced Ga-68 for molecular imaging	Michael K. Schultz (Iowa , US)
11:45-12:05	S 035	Design and development of universal chelating system to load Ga-68 for targeted radioimmunodiagnosis of cancer	Anil K Mishra (Delhi, India)
12:05-12:20	S 010	Electrochemical separation of 90-Y and development of 90Sr/90Y generator	A Dash (Mumbai, India)
12:20-12:35	S 003	Tracers for clinical PET: Looking beyond FDG	Ramam Chirakal (Ontario, Canada)
12:35-12:50	S 012	Development of novel Ga-68 labeled probes for imaging of infection and inflammation	Vijay Kumar (Sydney, Australia)
12:50-14:00	Lunch / Trade Exhibition / Poster Viewing		
14:00-15:30	<b>SCIENTIFIC SESSION II Ga-68 Molecular Imaging: A Worldwide Experience</b>		
	<b>Chairpersons</b>	<b>Arun Malhotra, RP Tripathi, Anil Bhansali, Ashok K Gupta</b>	<b>Speakers</b>
14:00-14:15	S 016	Ga-68 DOTATATE PET/CT in neuroendocrine tumors: PGIMER experience	BR Mittal (Chandigarh, India)
14:15-14:30	S 017	Ga-68 DOTA imaging - First experience	Jyotsna Rao (Hyderabad, India)
14:30-14:45	S 014	Ga-68 PET molecular imaging for diagnosis of neuroendocrine tumors- AIIMS experience	Rakesh Kumar (Delhi, India)
14:45-15:00	S 037	Imaging of Pulmonary carcinoid: The Iowa experience	Archana Laroia (IOWA, US)

15:00-15:15	S 018	Peptide receptor targeted radionuclide imaging and therapy in advanced metastatic thyroid carcinoma: exploiting the varying biology of metastases.	Gaurav Malhotra (Mumbai, India)
15:15-15:30	S 045	Current status of surgical options in the management of NET patients	Merten Hommann (Bad Berka, Germany)
<b>15:30-16:00 Tea / Trade Exhibition / Poster Viewing</b>			
<b>16:00-17:30 SCIENTIFIC SESSION III Molecular Imaging &amp; Therapy</b>			
<b>Chairpersons</b>		<b>Richard Baum, AK Singh, Gurpreet Singh, Rakesh Kapoor</b>	<b>Speakers</b>
16:00-16:20	S 049	Quantification and response assessment using molecular imaging - Where do we stand?	Winfried Brenner (Berlin, Germany)
16:20-16:40	S 023	Re-188-HEDP therapy of hormone refractory bone metastases of prostate and breast cancer: A retrospective analysis	Hans-Juergen Biersack (Bonn, Germany)
16:40-17:00	S 036	Recent progress with Ga-68 -labeled radiopharmaceuticals at MSKCC - Both in preclinical (NY, US) and clinical fronts	Naga V K Pillarsetty (NY, USA)
17:00-17:15	S 048	In Vivo evaluation of multifunctional DTTPA gold nanoparticles for molecular imaging.	Cathy Cutler (Missouri, US)
17:15-17:30	S 044	Development & Preclinical Evaluation of 68Ga-DO3P-AME-DO3P: A Polyazamacrocyclic Methylene Phosphonate for Diagnosis of Skeletal Metastases	Anupama Dutta (Delhi, India)
<b>17:30-18:40 SCIENTIFIC SESSION IV Oral Paper Presentation (Preclinical)</b>			
<b>Chairpersons</b>		<b>Vijay Sharma, Anupam Mondal, V Rangarajan, Jaya Shukla</b>	<b>Speakers</b>
17:30-17:40	O 001	Ga68-labeled compounds for infection imaging	Thomas Ebenhan (Pretoria, South Africa)
17:40-17:50	O 002	New NOTA based bisphosphonates for diagnosis of bone metastases.	Marian Meckel (Mainz, Germany)
17:50-18:00	O 003	Synthesis and biological evaluation of 68Ga(Chal)2DT as PET agent for A $\beta$ plaques in rain.	Kanchan Chauhan (Delhi, India)
18:00-18:10	O 004	Evaluation of Gallium-68 phosphonate complexes for bone Imaging using MicroPET.	Ambika Parmar (Delhi, India)
18:10-18:20	O 005	68Ga-Alpha-Fetoprotein peptide fragment for tumor imaging	A.A. Larenkov (Moscow, Russia)
18:20-18:30	O 006	Synthesis, characterization and radiolabeling of DTPA-doxorubicin complex with 68Ga as potential PET tumor imaging agent- A preclinical evaluation.	Pardeep Kumar (Chandigarh, India)
18:30-18:40	O 000	Chelators highly selective for Ga-68 and the practical consequences thereof	Jakub Šimeek (Munich, Germany)
<b>8:00 pm onwards Inaugural Dinner Venue Hotel Mountview, Sector-10, Chandigarh</b>			

## Friday, March 1, 2013

8:00 Onwards Registration

### 08:00-09:00 SCIENTIFIC SESSION V Oral Paper Presentations (Clinical & Dosimetry)

Chairpersons		Vikas Prasad, Vikram Lele, Anupama Dutta, SK Singh	Speakers
08:00-08:10	O 007	Gallium-68 compounds partly replace-18F-FDG in PET molecular imaging.	Kiran T (Bengaluru, India)
08:10-08:20	O 008	Detection of prostate cancer with the [68Ga]-labeled bombesin antagonist RM2 in patients undergoing radical prostatectomy.	Andre Mueller (Berlin, Germany)
08:20-08:30	O 009	Feasibility of Y-90 PET-CT following radioembolization.	Senthil R (Chennai, India)
08:30-08:40	O 010	Theranostics of neuroendocrine neoplasms: Molecular response and prognosis assessment after peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.	Harshad R. Kulkarni (Bad Berka, Germany)
08:40-08:50	O 011	The usage of deformable phantoms for personalized dosimetry in radionuclide therapy.	Matthias Blaickner (Vienna, Austria)
08:50-09:00	O 012	Guidelines for safe, effective outpatient Lutetium-177 Octreotate radiolabeled peptide therapy for neuroendocrine tumours and minimisation of radiation exposure of carers, hospital staff and general public.	Phillipe J Calais (Fremantle, Australia)

### 09:00-11:30 SCIENTIFIC SESSION VI Targeted Tumor Therapy with Beta Emitters

Chairpersons		Biersack HJ, BR Mittal, Cathy Cutler, Kallur KG	Speakers
09:00-09:20	S 008	Production of therapeutic radionuclides (177Lu and 90Y) for peptide receptor radionuclide therapy	Wouter A.P. Breeman Rotterdam, The Netherlands.
09:20-09:40	S 007	Options and availability of radionuclides for targeted therapy: Indian perspectives	M.R.A. Pillai (Mumbai, India)
09:40-10:00	S 020	Polish experience on PRRNT - Update 2012	Jolanta Kunikowska (Warsaw, Poland)
10:00-10:15		Indian experience on PRRNT	Sandeep Basu (Mumbai, India)
10:15-10:30	S 040	Radionuclide therapy in neuroendocrine tumors: current status and future prospects	Shaunak Naval Kissor (London, UK)
10:30-10:45	S 022	First African and South African experience on 177Lu PRRNT in NETs	Mike Sathegke (Pretoria, South Africa)
10:45-11:00	S 000	Neuroblastoma in Children- RN treatment strategies	Michael K Schultz (Iowa, US)
11:00-11:15	S 000	Lutetium therapy in metastatic pheochromocytoma.	Manoj K Bhatt (QLD, Australia)
11:15-11:30	S 000	PET tracers beyond FDG-our journey till date & road ahead	Mayukh Chakrabarty (Mumbai, India)

### 11:30-11:45 Tea / Trade Exhibition / Poster Viewing

### 11:45-13:15 SCIENTIFIC SESSION VII Targeted Tumor Therapy with Alpha Emitters

Chairpersons		George Weiner, Sudershan Bhatia, SC Sharma, MR Pillai	Speakers
11:45-12:00	S 043	Astatine-211: Production, chemistry & applications	Jean-François Gestin (Nantes, France)

12:00-12:15	S 028	Treatment of bladder cancer with Bi-213-anti-EGFR immuno-conjugates in a nude mouse model	Christof Seidl (Munich, Germany)
12:15-12:30	S 026	Targeted alpha particle therapy for acute myeloid leukemia	Joseph G. Jurcic (NY, US)
12:30-12:45	S 027	Glioblastoma therapy with substance P-213Bi - Initial Polish experience	Jolanta Kunikowska (Warsaw, Poland)
12:45-13:00	S 004	Pretargeting in solid tumors: Radioimmunotherapy results and Immuno-PET perspectives	François Kraeber Bodéré (Nantes, France)
13:00-13:15	S 029	Dosimetry for alpha-emitter-therapy: Approach to treatment planning	George Sgouros (Baltimore, US)
<b>13:15-14:15 Lunch / Trade Exhibition / Poster Viewing</b>			
<b>14:15-15:55 SCIENTIFIC SESSION VIII Integration of Molecular Imaging, Radionuclide Therapy and Surgery: THERANOSTICS on the Way to Personalized Medicine</b>			
<b>Chairpersons</b>		<b>Ajit Padhy, BA Krishna, Anil Mishra, CK Khosa, Arunanshu Behra</b>	<b>Speakers</b>
14:15-14:35	S 034	Peptides and receptors in image-guided therapy: Theranostics for neuroendocrine neoplasms	Richard P Baum (Bad Berka, Germany)
14:35-14:55	S 000	Liver Transplant in NET	A. S. Soin (Gurgaon India)
14:55-15:10	S 039	Lu-177 radiopharmaceuticals development at Bhabha Atomic Research Centre	Sharmila Banerjee (Mumbai, India)
15:10-15:30	S 025	Y-90 Radioembolization in liver tumors : The Iowa experience	Sandeep T Laroia (Iowa, US)
15:30-15:50	S 019	A bridge not to far: Personalized medicine with the use of theranostic radiopharmaceuticals	Suresh Srivastava (NY, US)
15:50-16:10		Multidisciplinary & integrated approach for personalized treatment in cancer cure	George Weiner (Iowa, US)
<b>15:55-16:15 Tea / Trade Exhibition / Poster Viewing</b>			
<b>16:15-18:15 SCIENTIFIC SESSION IX Integration of Molecular Imaging, Radionuclide Therapy and Surgery</b>			
<b>Chairpersons</b>		<b>Francoise Bordere, Michael Schultz, Sanjay Gambhir, Kanchan Mukherjee</b>	<b>Speakers</b>
16:15-16:35	S 000	Prognostic factors and outcome of pancreatic NET G1/2 after PRRT with Lu-177-octreotate	Samer Ezzidin (Bonn, Germany)
16:35-16:55	S 015	Personalized molecular imaging in NET - Lessons learnt in the past 10 years	Vikas Prasad (Berlin, Germany)
16:55-17:15	S 024	Dosimetry in peptide receptor radionuclide therapy: Methodology and practical experience	Christiane Schuchardt (Bad Berka, Germany)
17:15-17:35	S 046	Personalized approach to NET surgery-organ bank to immunohistochemistry and molecular imaging	Daniel Kaemmerer Bad Berka (Germany)
17:35-17:55	S 042	Targeted radionuclide therapy in the context of other systemic therapy for neuroendocrine tumors - Where we stand in 2013	Edward Wolin (LA, USA)
17:55-18:15	S 021	Peptide receptor radionuclide therapy (PRRT) with Lu-177-DOTA-Octreotate for patients with somatostatin receptor-expressing neuroendocrine tumors - The First U.S. phase I and II experience	Ebrahim S. Delpassand (Houston, US)
<b>8:00 pm onwards</b>		<b>Gala Dinner</b>	<b>Venue: Golden Tulip Resort</b>

## Saturday, March 2, 2013

<b>8:00 Onwards</b>	<b>Registration</b>		
<b>08:00-09:00</b>	<b>SCIENTIFIC SESSION X Oral Paper Presentation III Therapy</b>		
	<b>Chairpersons</b>	<b>GP Bandhopadhyay, Rao Papineni, Puja Panwar</b>	<b>Speakers</b>
08:00-08:10	O 013	225Ac and 213Bi $\alpha$ -particle-emitter therapy in combination with SAHA and 17-AAG.	Srinivasan Senthamizhchelvan (Karlsruhe, Germany)
08:10-08:20	O 014	Preparation and preliminary studies on 177Lu-labeled RGD :Peptide derivative for targeted tumor therapy	Sudipta Chakraborty (Mumbai, India)
08:20-08:30	O 015	Nano-carriers:A better alternative to amino acid co-infusion in PRRNT for renal protection.	Geetanjali Arora (Delhi, India)
08:30-08:40	O 016	Whether PRRT connecting with long acting somatostatin analogue may lengthen survival in group of patients with NET?	Anna Sowa-Staszczak (Krakow,Poland)
08:40-08:50	O 017	A DOTA-analog phosphinate chelator for application in multimeric bioconjugates and theranostics.	Johannes Notni (München, Germany)
08:50-09:00	O 018	Addition of erythropoietin is effective in stabilizing haemoglobin in patients with pre-existing grade-3 cancer induced anaemia needing radionuclide therapy for bone pain palliation.	Sukanta Barai (Lucknow, India)
<b>09:00-11:00</b>	<b>SCIENTIFIC SESSION XI Nanomedicine and Novel Approaches to Molecular Targeting</b>		
	<b>Chairpersons</b>	<b>Edward Wolin, Mike Sathekge, CM Pathak, Nand Relan</b>	<b>Speakers</b>
09:00-09:20	S 000	Improvement of the translational value of preclinical data	Marion de Jong (Rotterdam, Netherlands)
09:20-09:40	S 000	Genome to systems strategies enabling route to personalized medicine	Manoj Bhasin (Boston, US)
09:40-10:00	S 038	Ga-68-metalloprobes as molecular imaging agents for monitoring biomedical pathways in vivo	Vijay Sharma (St. Louis, US)
10:00-10:20	S 032	PET/MR in nano-medicine	George Loudos (Athens, Greece)
10:20-10:40	S 047	Design of optimized bifunctional chelating agents for the preparation of radiopharmaceuticals	Franck Denat Dijon, France
10:40-11:00	S 000	Advances in Functional Molecular Imaging: Sights on Inflammation, Infection, and Cancer.	Rao VL Papineni (Miami, US)
<b>11:00-11:15</b>	<b>Tea / Trade Exhibition / Poster Viewing</b>		
<b>11:15-13:15</b>	<b>SCIENTIFIC SESSION XII Hybrid Imaging in Cancer treatment</b>		
	<b>Chairpersons</b>	<b>SK Jindal, Seigo Kinuya, PS Soni, MS Sandhu</b>	<b>Speakers</b>
11:15-11:30	S 030	PET/CT based decision for treatment of lung cancer	Sudershan Bhatia (Iowa, US)
11:30-11:45	S 031	PET/CT in radiation therapy	Lakshmi Santanam (St. Louis, US)
11:45-12:00	S 000	Strength and Challenges in PET-MRI Imaging	Nand Relan (Stony Brooks, NY, US)

12:00-12:15	S 011	Role of endoscopic ultrasound in gastroenteropancreatic neuroendocrine tumors and update on their treatment	Surinder S Rana (Chandigarh, India)
12:15-12:30	S 000	The Role of PET Scan in radiation treatment planning & monitoring response after Stereotactic body radiotherapy of lung tumors	Ajay Sandhu (UCSD, USA)
<b>12:30-13:40 SCIENTIFIC SESSION XIII Oral Paper Presentation IV Radiopharmacy</b>			
<b>Chairpersons</b>		<b>Joseph Jurcic, BS Dwarkanath, PK Pradhan, Bikas Medhi</b>	<b>Speakers</b>
12:30-12:40	O 19	The NaCl based <sup>68</sup> Ga labeling procedure – a suitable method for research and clinical applications.	Dirk Mueller (Bad Berka, Germany)
12:40-12:50	O 20	<sup>68</sup> Ga-DOTA-substance-P as a tool for diagnostics & locoregional administration follow up of <sup>213</sup> Bi-DOTA-substance-P in the course of glioma therapy.	Dariusz Pawlak (Otwock, Poland)
12:50-13:00	O 21	Development of Ga-68 labeled novel peptide based imaging agent for neoplastic lesions and solid tumors.	Harleen Khurana (Delhi, India)
13:00-13:10	O 22	From bench to bedside with <sup>68</sup> Ga-TRAP radiopharmaceuticals: Synthesis, characterization, and clinical application of [ <sup>68</sup> Ga]TRAP(RGD) <sub>3</sub> .	Johannes Notni (München, Germany)
13:10-13:20	O 23	LAT I uptake of methionine based imaging probe labeled with <sup>68</sup> Gallium for the visualization of gliomas in vivo by PET.	Puja P. Hazari (Delhi, India)
13:20-13:30	O 24	Equilibrium, kinetic and structural studies of Gallium(III)-complexes formed with AAZTA ligand.	Zsolt Baranyai (Debrecen, Hungary)
13:30-13:40	O 000	<sup>68</sup> Ga-labelled cetuximab using cysteine based DTPA NCS for immuno-PET imaging of colorectal cancer	Jae Chiong Lim (Daejeon, Korea)
<b>13:40-14:30 Lunch / Trade Exhibition / Poster Viewing</b>			
<b>14:30-15:30 SCIENTIFIC SESSION XIV Patients' Session</b>			
<b>Chairpersons</b>		<b>Savita Malhotra (India) Jolanta Kunikowska (Poland) Sharmila Banerjee (India)</b>	<b>Speakers</b>
14:30-14:50	S 050	Patients view point Quality of life in oncological patients & radionuclide therapy	William Claxton (CNTS, Singapore)
14:50-15:00	S 000	NorCal CarciNET support group in US for NET patients	Josh Mailman (California,US)
15:00-15:30	S 000	On the Horizon – Radiopharmaceuticals for Molecular Imaging of Cancer	Hans-Jürgen Wester (München, Germany)
<b>15:30-17:00 SCIENTIFIC SESSION XV Congress Highlights</b>			
<b>Chairpersons</b>		<b>Hans-Jürgen Wester (Germany) Suresh Srivastava (US)</b>	<b>Speakers</b>
		Radiopharmacy/Chemistry/PreClinical	Michael K Schultz (Iowa, US)
		Clinical and PRRNT	Richard P. Baum (Bad Berka, Germany)
<b>Valedictory function with high tea</b>			